Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vernonia anthelmintica Willd Injection
- Development stage
- Preclinical
- Lead developer
- The Fifth Affiliated Hospital of Xinjiang Medical University
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
VAWI (Vernonia anthelmintica Willd Injection) is a Xinjiang Uygur medicine being investigated for the treatment of silicosis fibrosis. It is derived from the plant *Vernonia anthelmintica Willd*. Clinical trials are exploring its curative effects and the differences in serum protein expression in patients with silicosis fibrosis.
- Other names
- 驱虫斑鸠菊
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)ESR1 (ERα)IL-2 (Interleukin 2)TYR (Tyrosinase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on Vernonia anthelmintica Willd Injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vernonia anthelmintica Willd Injection.